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TBS was determined for L1-L4: TBS ⩾ 1.350 normal; 1.200-1.350 partially degraded; o1.200 degraded trabecular microarchitecture. 7 Throughout the transplant period, patients were prescribed 1200 mg elemental calcium, and 2000 IU vitamin D daily. Cyclosporine and short course methotrexate or mycophenolate mofetil were used for prevention of GvHD. Prednisone (2 mg/kg) was used for first-line treatment of grades II-IV acute GvHD.
At d100, the mean absolute decrease in lumbar spine BMD was 0.027 g/cm 2 , representing a decline of 3.0%. The mean absolute decrease in total hip and femoral neck BMD was 0.045 g/cm 2 and 0.047 g/cm 2 , representing a decline of 4.6% and 4.7%, respectively, ( Table 2) . BMD decline at hip sites was greater than at spine (P = 0.01 and P = 0.006, respectively) and women lost significantly more bone than men (Table 2) . Following allo-SCT, the frequency of osteoporosis increased from 12 to 18% (P o 0.001) and osteopenia increased from 41 to 50% (P = 0.002). In addition, by d100, two patients suffered six clinical spinal fractures; baseline characteristics and BMD changes for these patients are highlighted in Tables 1 and 2 , respectively. One patient had partially degraded baseline and d100 trabecular microarchitecture, whereas the other had normal baseline microarchitecture but partially degraded d100 microarchitecture.
Multivariate analysis of risk factors yielded an association between female gender and bone loss at lumbar spine (P = 0.041) and total hip (P = 0.004). Female gender was also the only factor significantly association with BMD loss ⩾ 5% at any site (P = 0.001). In contrast to prior studies, where this association was not found, we did not initiate hormone replacement therapy (HRT) until 3 months after allo-SCT due to concerns about venoocclusive disease. Therefore, hypogonadism may have contributed to early bone loss in our female patients.
We found that compared with reduced intensity chemotherapy, myeloablative chemotherapy (± TBI) was associated with bone loss at the spine (P = 0.044), and total hip (P = 0.018). In univariate analysis, significance was set as P o0.1, and myeloablative chemotherapy was the only factor significantly associated with femoral neck bone loss (P = 0.056), therefore, a multivariate analysis was not performed at this site. Stromal cells have the capacity to differentiate into osteoblasts but are of recipient origin, and thus subject to pre-transplant insults such as chemotherapy. 5 Ex vivo, osteoblast cell growth and function was significantly delayed in cultures obtained from bone marrow recipients treated with myeloablative chemotherapy ( ± TBI) as compared with cultures from healthy donors. Therefore, the resulting osteoblast impairment, in association with osteoclast activation, may lead to net bone loss. 5 In our study, patients who received myeloablative chemotherapy had an average hospital length of stay of 23.6 days compared with 17.4 days in patients pre-treated with reduced intensity chemotherapy (P o0.001). Therefore, the association between bone loss and myeloablative chemotherapy may reflect worse overall posttransplant health status.
Glucocorticoid treatment following transplant was only associated with bone loss at the total hip (P = 0.040). The association between glucocorticoids and bone loss at various sites has been inconsistent in previous studies. [1] [2] [3] [4] [5] The lack of association with spine BMD loss in our study is unexpected as trabecular bone loss occurs most rapidly in glucocorticoid-induced osteoporosis. 8 At the more cortical site, the femoral neck, the lack of association suggests that cortical bone loss occurs by a distinct mechanism.
In a previous study, analysis of cytokines and bone turnover markers in patients pre and post allo-SCT showed a positive correlation between femoral neck bone loss, the bone resorption marker C-terminal cross-linking telopeptide of type-1 collagen (β-CTX), and the osteoclastogenic cytokine monocyte chemoattractant protein 1.
9 Therefore, cytokine driven osteoclast differentiation may account for the large cortical bone loss seen by us and others. 1, [3] [4] [5] In addition, the impressive femoral neck bone loss observed following allo-SCT is reminiscent of cortical bone loss in patients with hyperparathyroidism, except the loss appears quite early. Translational studies have reported that lymphoid cells express parathyroid hormone (PTH) receptors and mice lacking T cells cannot induce osteoclast formation in response to PTH infusion and are resistant to cortical bone resorption. 10 Following allo-SCT the immune system is upregulated. Thus, cortical bone loss may result from an amplified interaction of lymphocytes with circulating PTH. In our study, the average vitamin D level pre-transplant was adequate, however, vitamin D levels were not available in all patients. Vitamin D insufficiency during transplant could induce secondary hyperparathyroidism with additional deleterious effects on cortical bone.
There was no association between BMD change and other factors examined including age (o 50 vs ⩾50), hematological disorder (ALL vs non-ALL), TBI, donor source (related vs unrelated) or GvHD (presence vs absence). Not all transplanted patients had paired dual x-ray absorptiometry scans, a requirement for study inclusion. Therefore we cannot exclude selection bias affecting our results.
We were able to calculate baseline and day 100 TBS for 121 patients. For the entire cohort, baseline TBS indicated normal trabecular microarchitecture (1.37 ± 0.099). However, following allo-SCT, TBS declined significantly in women (P = 0.006; mean of the difference 0.021). TBS also declined significantly in patients treated with any glucocorticoids (P = 0.009, mean of the difference 0.023), despite the lack of association between glucocorticoids and spine BMD loss. This finding supports the increased recognition that bone quality, rather than simply quantity, may predict fracture risk more accurately in glucocorticoid-induced osteoporosis. 8 Post-transplant bone loss is of great concern because it predisposes patients to future fractures with associated morbidity. In a recent report, patients post SCT had a significantly increased fracture risk compared with the general population. 11 To improve our understanding of bone loss following allo-SCT, future studies should include BMD measurements at the distal 1/3 forearm, a highly cortical site, given the apparent loss of cortical bone. Furthermore, quantitative CT of the hip can determine cortical volumetric BMD and high-resolution peripheral quantitative CT can assess cortical and trabecular microstructure at the distal radius and tibia. An additional consideration for post-allo-SCT Table 2 . Changes in bone mineral density at d100 following allo-SCT
DXA Site
All (n = 137) Female (n = 57) Male (n = 80) P-value (95% Abbreviations: BMD = bone mineral density; CI = confidence interval; DXA = dual-energy x-ray absorptiometry.
Letter to the Editor BMD decline is expansion of bone marrow adipose tissue, which is inversely related with BMD. 12 This possibility could be addressed using MRI.
Following allo-SCT, calcium, vitamin D and post-menopausal hormone replacement fail to prevent bone loss. 3, 4 Encouragingly, small studies have demonstrated that prophylactic bisphosphonate administration prior to allo-SCT can prevent, 13 or at least ameliorate post-transplant bone loss. 14 In conclusion, we found rapid decline in BMD following allo-SCT despite calcium and vitamin D supplementation. Patients with baseline osteoporosis by BMD criteria, or history of non-traumatic vertebral or hip fracture, should be treated with antiresorptive therapy. 15 However, the observed rapid bone loss supports using a lower threshold for pre-transplant intervention; osteopenia may be a reasonable cut-point. Our analysis suggested that early postallo-SCT bone loss was associated with female gender, glucocorticoids, and myeloablative chemotherapy. In addition, female gender and glucocorticoid exposure adversely impacted bone micro-architecture. Prior to transplant the chemotherapy regimen is known, facilitating patient selection for bisphosphonate therapy. Whether this patient selective approach for prophylactic treatment is effective will require prospective evaluation.
